• Something wrong with this record ?

Staining Performance of ALK and ROS1 Immunohistochemistry and Influence on Interpretation in Non-Small-Cell Lung Cancer

C. Keppens, J. von der Thüsen, P. Pauwels, A. Ryska, N. 't Hart, E. Schuuring, K. Miller, E. Thunnissen, K. Zwaenepoel, EMC. Dequeker

. 2020 ; 22 (12) : 1438-1452. [pub] 20201002

Language English Country United States

Document type Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22004785

Selection of non-small-cell lung cancer patients for treatment relies on the detection of expression of anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1 (ROS1) protein by immunohistochemistry (IHC). We evaluated staining performance for different IHC protocols and laboratory characteristics, and their influence on ALK and ROS1 interpretation during external quality assessment schemes between 2015 and 2018. Participants received five formalin-fixed, paraffin-embedded cases for staining by their routine protocol, whereafter at least two pathologists scored them simultaneously under a multihead microscope and awarded a graded expert staining score (ESS) from 1 to 5 points based on staining quality. European Conformity in Vitro Diagnostic kits (such as D5F3) revealed a better ALK ESS compared with laboratory-developed tests. ESS was indifferent to the applied antibody dilution or a recent protocol change. Lower ESSs were observed for higher antibody incubation times and temperatures. ESS for various ROS1 protocols were largely similar. Overall, for both markers, ESS improved over time and for repeated external quality assessment participation but was independent of laboratory setting or experience. Except for ROS1, ESS positively correlated with laboratory accreditation. IHC stains with lower ESS correlated with increased error rates in ALK and ROS1 interpretation and analysis failures. Laboratory characteristics differently affected staining quality and interpretation, and laboratories should assess both aspects, and less common protocols need improvement in staining performance.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004785
003      
CZ-PrNML
005      
20220228092437.0
007      
ta
008      
220113s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jmoldx.2020.09.006 $2 doi
035    __
$a (PubMed)33011443
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Keppens, Cleo $u Biomedical Quality Assurance Research Unit, Department of Public Health and Primary Care, University of Leuven, Leuven, Belgium
245    10
$a Staining Performance of ALK and ROS1 Immunohistochemistry and Influence on Interpretation in Non-Small-Cell Lung Cancer / $c C. Keppens, J. von der Thüsen, P. Pauwels, A. Ryska, N. 't Hart, E. Schuuring, K. Miller, E. Thunnissen, K. Zwaenepoel, EMC. Dequeker
520    9_
$a Selection of non-small-cell lung cancer patients for treatment relies on the detection of expression of anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1 (ROS1) protein by immunohistochemistry (IHC). We evaluated staining performance for different IHC protocols and laboratory characteristics, and their influence on ALK and ROS1 interpretation during external quality assessment schemes between 2015 and 2018. Participants received five formalin-fixed, paraffin-embedded cases for staining by their routine protocol, whereafter at least two pathologists scored them simultaneously under a multihead microscope and awarded a graded expert staining score (ESS) from 1 to 5 points based on staining quality. European Conformity in Vitro Diagnostic kits (such as D5F3) revealed a better ALK ESS compared with laboratory-developed tests. ESS was indifferent to the applied antibody dilution or a recent protocol change. Lower ESSs were observed for higher antibody incubation times and temperatures. ESS for various ROS1 protocols were largely similar. Overall, for both markers, ESS improved over time and for repeated external quality assessment participation but was independent of laboratory setting or experience. Except for ROS1, ESS positively correlated with laboratory accreditation. IHC stains with lower ESS correlated with increased error rates in ALK and ROS1 interpretation and analysis failures. Laboratory characteristics differently affected staining quality and interpretation, and laboratories should assess both aspects, and less common protocols need improvement in staining performance.
650    _2
$a anaplastická lymfomová kináza $x metabolismus $7 D000077548
650    _2
$a nemalobuněčný karcinom plic $x metabolismus $7 D002289
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $x metody $7 D007150
650    _2
$a hybridizace in situ fluorescenční $x metody $7 D017404
650    _2
$a laboratoře nemocniční $7 D007755
650    _2
$a nádory plic $x metabolismus $7 D008175
650    _2
$a patologové $7 D000072142
650    _2
$a tyrosinkinasy $x metabolismus $7 D011505
650    _7
$a protoonkogen Mas $7 D000090063 $2 czmesh
650    _2
$a protoonkogenní proteiny $x metabolismus $7 D011518
650    _2
$a senzitivita a specificita $7 D012680
655    _2
$a hodnotící studie $7 D023362
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a von der Thüsen, Jan $u Department of Pathology, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands
700    1_
$a Pauwels, Patrick $u Department of Pathology, University Hospital Antwerp, Edegem, Belgium; Centre for Oncological Research, University of Antwerp, Edegem, Belgium
700    1_
$a Ryska, Ales $u Department of Pathology, Charles University Medical Faculty Hospital, Hradec Kralove, Czech Republic
700    1_
$a 't Hart, Nils $u Department of Pathology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Department of Pathology, Isala Klinieken, Zwolle, the Netherlands
700    1_
$a Schuuring, Ed $u Department of Pathology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
700    1_
$a Miller, Keith $u UK National External Quality Assessment Scheme for Immunocytochemistry and in Situ Hybridisation, University College London Cancer Institute, London, United Kingdom
700    1_
$a Thunnissen, Erik $u Department of Pathology, Vrije Universiteit Amsterdam Medical Center, Amsterdam, the Netherlands
700    1_
$a Zwaenepoel, Karen $u Department of Pathology, University Hospital Antwerp, Edegem, Belgium; Centre for Oncological Research, University of Antwerp, Edegem, Belgium
700    1_
$a Dequeker, Elisabeth M C $u Biomedical Quality Assurance Research Unit, Department of Public Health and Primary Care, University of Leuven, Leuven, Belgium. Electronic address: els.dequeker@kuleuven.be
773    0_
$w MED00012712 $t The Journal of molecular diagnostics : JMD $x 1943-7811 $g Roč. 22, č. 12 (2020), s. 1438-1452
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33011443 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220228092435 $b ABA008
999    __
$a ok $b bmc $g 1752083 $s 1155934
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 22 $c 12 $d 1438-1452 $e 20201002 $i 1943-7811 $m The Journal of molecular diagnostics $n J Mol Diagn $x MED00012712
LZP    __
$a Pubmed-20220113

Find record

Citation metrics

Archiving options